{"doi":"10.1900/rds.2016.13.212","title":"Benefits of Rosuvastatin in Cardiovascular Protection Remain Unclear After HOPE-3","abstract":null,"journal":"The Review of Diabetic Studies","year":2016,"id":621537,"datarank":0.20794415416798362,"base_score":1.3862943611198906,"endowment":1.3862943611198906,"self_citation_contribution":0.20794415416798362,"citation_network_contribution":0.0,"self_endowment_contribution":0.20794415416798362,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":3,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1605093,"name":"Der-Wei Hwu","orcid":null,"position":1,"is_corresponding":false},{"id":1605094,"name":"Wei-Pin Kao","orcid":null,"position":2,"is_corresponding":false},{"id":1605095,"name":"Yau-Jiunn Lee","orcid":null,"position":3,"is_corresponding":false},{"id":1605092,"name":"Yu-Hung Chang","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Benefits of Rosuvastatin in Cardiovascular Protection Remain Unclear After HOPE-3","abstract":"The Review of Diabetic Studies,2016,13,4,212-214.DOI:10.1900/RDS.2016.13.212Published:February 2017Type:Letter to EditorAuthors:Yu-Hung Chang, Der-Wei Hwu, Wei-Pin Kao, and Yau-Jiunn Lee Author(s) affiliations:Yu-Hung Chang1, Der-Wei Hwu1,2, Wei-Pin Kao3, and Yau-Jiunn Lee1 1Lee’s Endocrinology Clinic, 130 Min-Tzu Rd, Pingtung 90000, TAIWAN. 2Graduate Institute of Clinical Medicine, Kaohsiung Medical University, 100 Shih-Chuan 1st Road, Kaohsiung 80708, TAIWAN. 3MoonCome Cardiovascular Clinic, 318 Heti Rd, Sanmin Dist., Kaohsiung City 80794, TAIWAN. Abstract:The use of commercialized statins in the prevention of cardiovascular diseases (CVD) has commonly been accepted based on the informative results of the Cholesterol Treatment Trialists (CTT) reports [1] As an additional effort in the prevention of CVD, professional societies have issued practical recommendations for healthcare providers on the effective use of statins in lowering low-density-lipoprotein cholesterol (LDL-C)[2]. Among these statins, atorvastatin and rosuvastatin are regarded as the most effective as they can reduce more than 30% of LDL-C, even at low doses (i.e. atorvastatin 10 mg; rosuvastatin 5 mg) [2]. The results of the recent HOPE-3 study [3], in which 10 mg rosuvastatin was found to reduce the development of CVD by 24% in intermediate-risk persons, may reinforce the role of rosuvastatin in CVD prevention. However, there are some concerns regarding the use of rosuvastatin. Keywords:NilView:PDF (145.46 KB)","is_dataset_classified":null,"base_score":1.3862943611198906,"endowment":1.3862943611198906,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"28278306","pmcid":"PMC5734220","openalex_id":"https://openalex.org/W3022278114","authors":[],"funders":[],"total_grants":0,"fwci":0.0,"citation_percentile":0.34925981,"influential_citations":0,"citation_trend":[{"year":2021,"count":1},{"year":2023,"count":1},{"year":2025,"count":1}],"oa_status":"bronze","license":null,"oa_locations":[{"url":"http://www.soc-bdr.org/content/e4/e887/volRdsVolumes17236/issRdsIssues18734/chpRdsChapters18744/strRdsArticles18745/?preview=preview&showpdf=1","host_type":"journal"},{"url":"http://www.soc-bdr.org/content/e4/e887/volRdsVolumes17236/issRdsIssues18734/chpRdsChapters18744/strRdsArticles18745/?preview=preview&showpdf=1","host_type":"publisher"},{"url":"https://doi.org/10.1900/rds.2016.13.212","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/28278306","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/5734220","host_type":"repository"}],"fields_of_study":["Lipoproteins and Cardiovascular Health","Diabetes, Cardiovascular Risks, and Lipoproteins","Health Systems, Economic Evaluations, Quality of Life"],"mesh_terms":[],"keywords":["Rosuvastatin","Atorvastatin","Medicine","Statin","Internal medicine"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-03T14:58:00.682402Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}